Effect of spironolactone on diastolic function and left ventricular mass in Maine coon cats with familial hypertrophic cardiomyopathy

Journal of Veterinary Internal Medicine

Volumn 22, Issue 2, 2008, Pages 335-341

  MacDonald, Kristin A ^a,b   Kittleson, M D ^a,b   Kass, P H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Animal Care Center of Sonoma   (United States)

Author keywords

Aldosterone; Early mitral annular velocity; Mineralocorticoid receptor blocker; Tissue Doppler imaging; Ulcerative dermatitis

Indexed keywords

DIURETIC AGENT; SPIRONOLACTONE;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DRUG EFFECT; DRUG ERUPTION; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENETIC PREDISPOSITION; GENETICS; HEART VENTRICLE; MALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANALYSIS OF VARIANCE; ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CAT DISEASES; CATS; DIASTOLE; DIURETICS; DRUG ERUPTIONS; GENETIC PREDISPOSITION TO DISEASE; HEART VENTRICLES; MALE; SPIRONOLACTONE;

EID: 42449144778     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0049.x     Document Type: Article

References (34)

1. Marian AJ, Salek L, Lutucuta S. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med 2001;92:435-451.
2. Meurs KM, Sanchez X, David RM, et al. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet 2005;14:3587-3593.
3. Liu SK, Roberts WC, Maron BJ. Comparison of morphologic findings in spontaneously occurring hypertrophic cardiomyopathy in humans, cats and dogs. Am J Cardiol 1993;72:944-951.
4. Kittleson MD, Meurs KM, Munro MJ, et al. Familial hypertrophic cardiomyopathy in Maine Coon cats: An animal model of human disease. Circulation 1999;99:3172-3180.
5. Golden AL, Bright JM. Use of relaxation half-time as an index of ventricular relaxation in clinically normal cats and cats with hypertrophic cardiomyopathy. Am J Vet Res 1990;51:1352-1356.
6. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res 2000;45:813-825.
7. Ohsato K, Shimizu M, Sugihara N, et al. Histopathological factors related to diastolic function in myocardial hypertrophy. Jpn Circ J 1992;56:325-333.
8. Varnava AM, Elliott PM, Mahon N, et al. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001;88:275-279.
9. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000;35:36-44.
10. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-1785.
11. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109:1284-1291.
12. Taugner FM. Stimulation of the renin-angiotensin system in cats with hypertrophic cardiomyopathy. J Comp Pathol 2001;125:122-129.
13. MacDonald K, Kittleson MD, Larson RF, et al. The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy with no heart failure. J Vet Intern Med 2006;20:1093-1105.
14. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993;73:413-423.
15. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial flbrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.
16. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26: 809-820.
17. MacDonald KA, Kittleson MD, Larson R, Wisner ER. Cardiac magnetic resonance imaging more accurately quantifies left ventricular mass than echocardiography in cats. Vet Radiol Ultrasound 2004;46:192-199.
18. Gavaghan BJ, Kittleson MD, Fisher KJ, et al. Quantification of left ventricular diastolic wall motion by Doppler tissue imaging in healthy cats and cats with cardiomyopathy. Am J Vet Res 1999;60:1478-1486.
19. Rousseau MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40:1596-1601.
20. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-1233.
21. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-2972.
22. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647-H654.
23. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-1673.
24. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: A pilot study. Circulation 2005;112:2940-2945.
25. Cicoira M, Rossi A, Bonapace S, et al. Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am J Med 2004;116: 657-661.
26. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
27. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-1388.
28. Perkins MJ, Van Driest SL, Ellsworth EG, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005;26: 2457-2462.
29. Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808-1812.
30. Monteiro DR, Kriegel AJ, Greene AS. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy. J Cardiovasc Pharmacol 2006;48:265-273.
31. Cutaneous drug reaction case reports: From the world literature. Am J Clin Dermatol 2003;4:365-370.
32. Gupta AK, Knowles SR, Shear NH. Spironolactone-associated cutaneous effects: A case report and a review of the literature. Dermatology 1994;189:402-405.
33. Uddin MS, Lynfield YL, Grosberg SJ, Stiefler R. Cutaneous reaction to spironolactone resembling lupus erythematosus. Cutis 1979;24:198-200.
34. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005;165: 869-874.